A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Jun 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Denosumab (Primary)
Indications Adenocarcinoma; Biliary cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer
Focus Therapeutic Use
Acronyms ESPRESSO-02

Most Recent Events

19 Apr 2018 Trial design presented at the 2018 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
17 Feb 2018 Status changed from recruiting to active, no longer recruiting.
02 Aug 2017 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight